

---

**Press Release****DIASORIN LAUNCHES 3 NEW PRIMER PAIRS FOR USE IN MOLECULAR TESTING: PNEUMOCYSTIS JIROVECI, GROUP C STREPTOCOCCUS, AND GROUP G STREPTOCOCCUS**

**July 28, 2017 - Saluggia (VC)** - DiaSorin (FTSE Italia Mid Cap: DIA) announced today that they have launched three new Primer Pairs for use in molecular testing as part of laboratory developed tests (LDTs).

The Group C Streptococcus, Group G Streptococcus, and Pneumocystis jirovecii Primer Pairs were developed by DiaSorin Molecular LLC in Cypress, California. The addition of these three Primer Pairs contributes to a menu of over 60 molecular reagents that target bacterial, viral, and fungal targets as well as human genetic mutations.

The Group C and G Streptococcus add to the streptococcus product line which also includes Group A Strep and Group B Strep. Group C and G Strep are isolates of streptococci that react with Lancefield group C or G typing serum, respectively.

Pneumocystis jirovecii which had previously been classified as Pneumocystis carinii is our first infectious disease fungal target.

*“DiaSorin Molecular’s line of molecular reagents for infectious disease testing provides laboratories the ability to develop a robust menu of nucleic acid tests based on the needs of their patient population,”* said Michelle Tabb, Vice President of Research and Development, DiaSorin Molecular LLC. *“Laboratories are better able to customize assay designs, improve test availability and control costs with access to commercially developed molecular reagents.”*

In the US, our Primer Pairs are classified as Analyte Specific Reagents (ASRs) which are utilized by high complexity laboratories in LDTs when an FDA cleared or approved kit might not otherwise be available.

*“DiaSorin Molecular continues its commitment to customers in the ongoing design and development of Primer Pairs needed to empower laboratories with accessibility to reagents for molecular assays,”* commented Carlo Rosa, Chief Executive Officer of DiaSorin Group. *“Our new Primer Pairs, as well as the recently released Simplexa™ C. difficile Direct were selected for development in response to requests from our customers.”*

**About DiaSorin**

Headquartered in Italy and listed in the FTSE Italia Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnosics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnosics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the IVD “diagnostics specialist”.

**For additional information, please contact:**

**Riccardo Fava**

Investor Relations & Corporate Communication Senior Director

Tel: +39.0161.487988

[riccardo.fava@diasorin.it](mailto:riccardo.fava@diasorin.it)

**Ines Di Terlizzi**

Investor Relator

Tel: +39.0161.487567

[ines.diterlizzi@diasorin.it](mailto:ines.diterlizzi@diasorin.it)